Loading…

Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa

Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administ...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical pharmacy 2016-02, Vol.38 (1), p.70-79
Main Authors: Cotrina-Luque, Jesús, Gil-Navarro, Maria Victoria, Acosta-García, Héctor, Alfaro-Lara, Eva Rocío, Luque-Márquez, Rafael, Beltrán-García, Margarita, Bautista-Paloma, Francisco Javier
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3
cites cdi_FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3
container_end_page 79
container_issue 1
container_start_page 70
container_title International journal of clinical pharmacy
container_volume 38
creator Cotrina-Luque, Jesús
Gil-Navarro, Maria Victoria
Acosta-García, Héctor
Alfaro-Lara, Eva Rocío
Luque-Márquez, Rafael
Beltrán-García, Margarita
Bautista-Paloma, Francisco Javier
description Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to Pseudomonas aeruginosa . Setting Multicenter clinical trial with 11 third level Spanish hospitals. Method Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II). Main outcome measure Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported. Results 78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported. Conclusion Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.
doi_str_mv 10.1007/s11096-015-0208-y
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1792381530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3937133541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3</originalsourceid><addsrcrecordid>eNqNkUFrHSEQx6U0NCHNB8ilLPTSyyYzurrrsTyaNhDopT2Lq24w7OpW3ZbXT18fLw2hEKiXmdHf_HX8E3KJcIUA_XVGBClaQN4ChaHdvyJnlCK0fY_4-ikHdkoucn6AujpBkXdvyCkVXd8NAs_Ir10MxYctbrn56VKuwYfi0uJLcaE0q19d0sbPsw_XRf-OozZFLxWatuxjqMkhd6YcCru5psQmpqYKrXXT2WbNbrNxiUHnRru03fsQs35LTiY9Z3fxGM_J95tP33Zf2ruvn293H-9a0_W8tJZNtDPA7KCt6DUKkNyOY2cHqrVwkuEojTCSSQScpql-BLdgB6k1dgiOnZMPR901xR-by0UtPhs3zzq4OrPCXlI2IGfwH2jPJHDgvKLv_0Ef4pZCHaRSAusrGA6VwiNlUsw5uUmtyS867RWCOniojh6q6qE6eKj2tefdo_I2Ls4-dfx1rAL0COR6FO5denb1i6p_ALxbqWM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1761208318</pqid></control><display><type>article</type><title>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</title><source>Springer Nature</source><creator>Cotrina-Luque, Jesús ; Gil-Navarro, Maria Victoria ; Acosta-García, Héctor ; Alfaro-Lara, Eva Rocío ; Luque-Márquez, Rafael ; Beltrán-García, Margarita ; Bautista-Paloma, Francisco Javier</creator><creatorcontrib>Cotrina-Luque, Jesús ; Gil-Navarro, Maria Victoria ; Acosta-García, Héctor ; Alfaro-Lara, Eva Rocío ; Luque-Márquez, Rafael ; Beltrán-García, Margarita ; Bautista-Paloma, Francisco Javier</creatorcontrib><description>Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to Pseudomonas aeruginosa . Setting Multicenter clinical trial with 11 third level Spanish hospitals. Method Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II). Main outcome measure Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported. Results 78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported. Conclusion Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.</description><identifier>ISSN: 2210-7703</identifier><identifier>EISSN: 2210-7711</identifier><identifier>DOI: 10.1007/s11096-015-0208-y</identifier><identifier>PMID: 26474861</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject><![CDATA[Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - adverse effects ; Bacterial Load ; Cross Infection - diagnosis ; Cross Infection - drug therapy ; Cross Infection - microbiology ; Double-Blind Method ; Drug Administration Schedule ; Drug therapy ; Female ; Humans ; Infections ; Infusions, Intravenous ; Internal Medicine ; Intravenous therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Penicillanic Acid - administration & dosage ; Penicillanic Acid - adverse effects ; Penicillanic Acid - analogs & derivatives ; Pharmacy ; Piperacillin - administration & dosage ; Piperacillin - adverse effects ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - growth & development ; Pseudomonas aeruginosa - isolation & purification ; Pseudomonas Infections - diagnosis ; Pseudomonas Infections - drug therapy ; Pseudomonas Infections - microbiology ; Remission Induction ; Research Article ; Side effects ; Spain ; Time Factors ; Treatment Outcome ; Young Adult]]></subject><ispartof>International journal of clinical pharmacy, 2016-02, Vol.38 (1), p.70-79</ispartof><rights>Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015</rights><rights>Springer International Publishing 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3</citedby><cites>FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26474861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cotrina-Luque, Jesús</creatorcontrib><creatorcontrib>Gil-Navarro, Maria Victoria</creatorcontrib><creatorcontrib>Acosta-García, Héctor</creatorcontrib><creatorcontrib>Alfaro-Lara, Eva Rocío</creatorcontrib><creatorcontrib>Luque-Márquez, Rafael</creatorcontrib><creatorcontrib>Beltrán-García, Margarita</creatorcontrib><creatorcontrib>Bautista-Paloma, Francisco Javier</creatorcontrib><title>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</title><title>International journal of clinical pharmacy</title><addtitle>Int J Clin Pharm</addtitle><addtitle>Int J Clin Pharm</addtitle><description>Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to Pseudomonas aeruginosa . Setting Multicenter clinical trial with 11 third level Spanish hospitals. Method Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II). Main outcome measure Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported. Results 78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported. Conclusion Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Bacterial Load</subject><subject>Cross Infection - diagnosis</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - microbiology</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Infections</subject><subject>Infusions, Intravenous</subject><subject>Internal Medicine</subject><subject>Intravenous therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Penicillanic Acid - administration &amp; dosage</subject><subject>Penicillanic Acid - adverse effects</subject><subject>Penicillanic Acid - analogs &amp; derivatives</subject><subject>Pharmacy</subject><subject>Piperacillin - administration &amp; dosage</subject><subject>Piperacillin - adverse effects</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - growth &amp; development</subject><subject>Pseudomonas aeruginosa - isolation &amp; purification</subject><subject>Pseudomonas Infections - diagnosis</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Pseudomonas Infections - microbiology</subject><subject>Remission Induction</subject><subject>Research Article</subject><subject>Side effects</subject><subject>Spain</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>2210-7703</issn><issn>2210-7711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkUFrHSEQx6U0NCHNB8ilLPTSyyYzurrrsTyaNhDopT2Lq24w7OpW3ZbXT18fLw2hEKiXmdHf_HX8E3KJcIUA_XVGBClaQN4ChaHdvyJnlCK0fY_4-ikHdkoucn6AujpBkXdvyCkVXd8NAs_Ir10MxYctbrn56VKuwYfi0uJLcaE0q19d0sbPsw_XRf-OozZFLxWatuxjqMkhd6YcCru5psQmpqYKrXXT2WbNbrNxiUHnRru03fsQs35LTiY9Z3fxGM_J95tP33Zf2ruvn293H-9a0_W8tJZNtDPA7KCt6DUKkNyOY2cHqrVwkuEojTCSSQScpql-BLdgB6k1dgiOnZMPR901xR-by0UtPhs3zzq4OrPCXlI2IGfwH2jPJHDgvKLv_0Ef4pZCHaRSAusrGA6VwiNlUsw5uUmtyS867RWCOniojh6q6qE6eKj2tefdo_I2Ls4-dfx1rAL0COR6FO5denb1i6p_ALxbqWM</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Cotrina-Luque, Jesús</creator><creator>Gil-Navarro, Maria Victoria</creator><creator>Acosta-García, Héctor</creator><creator>Alfaro-Lara, Eva Rocío</creator><creator>Luque-Márquez, Rafael</creator><creator>Beltrán-García, Margarita</creator><creator>Bautista-Paloma, Francisco Javier</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</title><author>Cotrina-Luque, Jesús ; Gil-Navarro, Maria Victoria ; Acosta-García, Héctor ; Alfaro-Lara, Eva Rocío ; Luque-Márquez, Rafael ; Beltrán-García, Margarita ; Bautista-Paloma, Francisco Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Bacterial Load</topic><topic>Cross Infection - diagnosis</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - microbiology</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Infections</topic><topic>Infusions, Intravenous</topic><topic>Internal Medicine</topic><topic>Intravenous therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Penicillanic Acid - administration &amp; dosage</topic><topic>Penicillanic Acid - adverse effects</topic><topic>Penicillanic Acid - analogs &amp; derivatives</topic><topic>Pharmacy</topic><topic>Piperacillin - administration &amp; dosage</topic><topic>Piperacillin - adverse effects</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - growth &amp; development</topic><topic>Pseudomonas aeruginosa - isolation &amp; purification</topic><topic>Pseudomonas Infections - diagnosis</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Pseudomonas Infections - microbiology</topic><topic>Remission Induction</topic><topic>Research Article</topic><topic>Side effects</topic><topic>Spain</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cotrina-Luque, Jesús</creatorcontrib><creatorcontrib>Gil-Navarro, Maria Victoria</creatorcontrib><creatorcontrib>Acosta-García, Héctor</creatorcontrib><creatorcontrib>Alfaro-Lara, Eva Rocío</creatorcontrib><creatorcontrib>Luque-Márquez, Rafael</creatorcontrib><creatorcontrib>Beltrán-García, Margarita</creatorcontrib><creatorcontrib>Bautista-Paloma, Francisco Javier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database (ProQuest)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cotrina-Luque, Jesús</au><au>Gil-Navarro, Maria Victoria</au><au>Acosta-García, Héctor</au><au>Alfaro-Lara, Eva Rocío</au><au>Luque-Márquez, Rafael</au><au>Beltrán-García, Margarita</au><au>Bautista-Paloma, Francisco Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa</atitle><jtitle>International journal of clinical pharmacy</jtitle><stitle>Int J Clin Pharm</stitle><addtitle>Int J Clin Pharm</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>38</volume><issue>1</issue><spage>70</spage><epage>79</epage><pages>70-79</pages><issn>2210-7703</issn><eissn>2210-7711</eissn><abstract>Background There is lack of information on the efficacy and safety of piperacillin–tazobactam administered by continuous infusion. Objective The aim of this study was to investigate whether continuous infusion of piperacillin–tazobactam is superior in terms of efficacy to a 30 % higher dose administered by intermittent infusion to treat suspected or confirmed infection due to Pseudomonas aeruginosa . Setting Multicenter clinical trial with 11 third level Spanish hospitals. Method Randomized, double-blind parallel-group clinical trial, controlled by conventional administration of the drug. Patients randomly assigned in a 1:1 ratio to receive piperacillin–tazobactam as continuous infusion (CI) or intermittent (II). Main outcome measure Primary efficacy endpoint was percentage of patients having a satisfactory clinical response at completion of treatment, defined as clinical cure or clinical improvement. Adverse events were reported. Results 78 patients were included, 40 in the CI group and 38 in the II group. Mean (standard deviation) duration of treatment was 7 (±4.44) days. 58 patients (74.4 %) experienced cure or improvement at the end of the treatment. There were no statistical differences in cure rates between the two treatment arms and no adverse events were reported. Conclusion Continuous infusion of piperacillin–tazobactam is an alternative administration drug method at least similar in efficacy and safety to conventional intermittent infusion. Multivariate analysis is needed to determine whether continuous administration might be more beneficial than intermittent in certain patient subgroups.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>26474861</pmid><doi>10.1007/s11096-015-0208-y</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2210-7703
ispartof International journal of clinical pharmacy, 2016-02, Vol.38 (1), p.70-79
issn 2210-7703
2210-7711
language eng
recordid cdi_proquest_miscellaneous_1792381530
source Springer Nature
subjects Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - adverse effects
Bacterial Load
Cross Infection - diagnosis
Cross Infection - drug therapy
Cross Infection - microbiology
Double-Blind Method
Drug Administration Schedule
Drug therapy
Female
Humans
Infections
Infusions, Intravenous
Internal Medicine
Intravenous therapy
Male
Medicine
Medicine & Public Health
Middle Aged
Penicillanic Acid - administration & dosage
Penicillanic Acid - adverse effects
Penicillanic Acid - analogs & derivatives
Pharmacy
Piperacillin - administration & dosage
Piperacillin - adverse effects
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Pseudomonas aeruginosa - growth & development
Pseudomonas aeruginosa - isolation & purification
Pseudomonas Infections - diagnosis
Pseudomonas Infections - drug therapy
Pseudomonas Infections - microbiology
Remission Induction
Research Article
Side effects
Spain
Time Factors
Treatment Outcome
Young Adult
title Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T13%3A13%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Continuous%20versus%20intermittent%20piperacillin/tazobactam%20infusion%20in%20infection%20due%20to%20or%20suspected%20pseudomonas%20aeruginosa&rft.jtitle=International%20journal%20of%20clinical%20pharmacy&rft.au=Cotrina-Luque,%20Jes%C3%BAs&rft.date=2016-02-01&rft.volume=38&rft.issue=1&rft.spage=70&rft.epage=79&rft.pages=70-79&rft.issn=2210-7703&rft.eissn=2210-7711&rft_id=info:doi/10.1007/s11096-015-0208-y&rft_dat=%3Cproquest_cross%3E3937133541%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-d3f24c03d8ad67a16095dbb4d82aa6e931b9c6c939101fff2085d0d89aa1410e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1761208318&rft_id=info:pmid/26474861&rfr_iscdi=true